Physician Assistant · Newport, TN
NPI
1922670389
Since 2021
Specialty
Physician Assistant
Code 363A00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
150 E Broadway
Newport, TN, 37821
Phone (423) 223-7690
Groups this clinician bills Medicare through
Medicare paid, 2024
$42K
805 services
Medicare patients, 2024
444
Average age 74
Drug cost, 2024
$1.9M
3,717 prescriptions
Company payments, 2025
$1,907
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lexis D Carter was code 99214 (office e&m - established), 376 times for 274 patients. In total Lexis D Carter billed 805 services in 23 codes, and Medicare paid $42K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 376 | 274 | $73.40 | $28K |
| 99213 Office E&M - Established | Office | 252 | 219 | $49.37 | $12K |
| 99406 Behavioral Health Services | Office | 43 | 32 | $11.46 | $493 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 30 | 21 | $0.71 | $21.36 |
| 36415 Venipuncture Blood Collection | Office | 24 | 21 | $8.65 | $208 |
| 96372 Injection Administration | Office | 23 | 20 | $7.87 | $181 |
| 71046 X-ray - Chest | Office | 14 | 14 | $17.43 | $244 |
By year: 2022 $19K for 209 services; 2023 $38K for 699 services; 2024 $42K for 805 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 24 | 21 | $8.65 | $208 |
Medicare prescription drug claims, 2024
In 2024, the drug Lexis D Carter prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 584 prescriptions and refills. In total Lexis D Carter wrote 3,717 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 584 | 649 | 230 | $12K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 575 | 657 | 149 | $428K |
| Prednisone Generic | 243 | 262 | 120 | $1,403 |
| Montelukast Sodium Generic | 239 | 448 | 69 | $1,532 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 231 | 272 | 71 | $174K |
| Roflumilast Generic | 148 | 206 | 44 | $16K |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 136 | 165 | 42 | $77K |
| Spiriva Respimat Tiotropium Bromide | 122 | 166 | 37 | $87K |
| Methylprednisolone Generic | 117 | 117 | 111 | $1,144 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 116 | 133 | 38 | $18K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 107 | 127 | 29 | $58K |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 92 | 92 | 84 | $1,275 |
| Doxycycline Hyclate Generic | 90 | 90 | 88 | $972 |
| Symbicort Budesonide/Formoterol Fumarate | 67 | 87 | 22 | $20K |
| Azithromycin Generic | 55 | 55 | 40 | $329 |
Brand drugs: 1,919 claims; generic drugs: 1,798 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lexis D Carter $1,907 ($1,907 in general payments such as food, travel and fees) from 34 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $217.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 7 | $217 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 21 | $178 |
| Abbvie Inc. ABBV | 12 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 6 | $128 |
| GlaxoSmithKline, LLC. GSK | 7 | $111 |
| Viatris Specialty LLC | 5 | $97.48 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $79.95 |
| Mallinckrodt Hospital Products Inc. | 3 | $70.5 |
| Lilly USA, LLC LLY | 4 | $67.71 |
| Axsome Therapeutics, Inc. AXSM | 3 | $57.64 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.